Syros Pharmaceuticals (SYRS) Tops Q4 EPS by 9c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Syros Reports Fourth Quarter and Full Year 2021 Financial Results and Highlights Key Accomplishments and Upcoming Milestones
March 15, 2022 7:32 AM EDTOn Track to Report PK and Safety Data from Ongoing Dose Confirmation Study of SY-2101 in Mid-2022
Expect to Report Clinical Activity from the Safety Lead-In Portions of the Ongoing SELECT-AML-1 Trial of Tamibarotene and the Expansion Cohort of SY-5609 in Pancreatic Cancer in 2H 2022
Expect to Initiate Phase 1 Trial of SY-5609 in Hematologic Malignancies in 2H 2022
New Preclinical Data on CDK12 Inhibitor to be Presented at AACR; On Track to Name Next Development Candidate in 2H 2022
... More